Exploring the implications of the delamanid phase III and STREAM trial results
The first ever phase III trials for multidrug-resistant TB (MDR-TB) have finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 12 December 2017 at 8:30 a.m. EST to explore implications for the field, from the delamanid C213 trial and the STREAM trial to evaluate the shorter regimen for MDR-TB.
Dr. Francesca Conradie, Wits University
Dr. Carole Diane Mitnick, Harvard Medical School
Marcus Low, Spotlight
Mandy Slutsker, ACTION
Moderator: Erica Lessem, TAG
To register, click here.